ArticleJournal of studies on alcohol and drugs2026
Intravenous Buprenorphine Reversed Opioid-Induced Respiratory Depression Without Precipitating Withdrawal in Emergency Department Patients.
Article in Journal of studies on alcohol and drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveBuprenorphine is a high-affinity partial agonist that can displace full opioid agonists and could be used to reverse opioid-induced respiratory depression. There is scant evidence to support the use of buprenorphine in an acute opioid overdose to reverse respiratory depression in the era of high fentanyl prevalence in the drug supply. This is a case series of four patients with signs and symptoms of an opioid overdose who showed clinical improvement after receiving intravenous buprenorphine.
methodA case series of adult emergency department patients treated at a single urban academic medical center was reviewed by the authors, who determined by consensus whether there was evidence of an acute opioid overdose and if those signs and symptoms were improved after receiving intravenous buprenorphine.
resultsAll four cases were male patients with a history of opioid use disorder who were treated in the emergency department after an opioid overdose and had signs of respiratory depression. Three of the four cases received naloxone before receiving intravenous buprenorphine. Initial doses of intravenous buprenorphine ranged from 0.1 mg to 0.15 mg. None of the patients developed buprenorphine-precipitated withdrawal. All of the cases were discharged from the emergency department with a prescription for sublingual buprenorphine.
conclusionsIn this case series, patients who received intravenous buprenorphine after an acute opioid overdose had some clinical improvement and did not develop buprenorphine-precipitated withdrawal. Further research should be performed to determine the safety and efficacy of intravenous buprenorphine as an opioid overdose reversal agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.